TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Moderate to Severe Platysma Prominence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must voluntarily sign and date an informed consent, approved by an independent ethics committee (IEC)/institutional review board (IRB), prior to the initiation of any screening or study specific procedures~* Are willing and able to comply with procedures required in the protocol~* Adult male or female, at least 18 years old at the time of signing the informed consent~* Good health as determined by medical history, physical examination, vital signs, and investigator's judgment~Exclusion Criteria:~* Any medical condition that may put the participant at increased medical risk with exposure to BOTOX, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other condition that might interfere with neuromuscular function~* Participant has an anticipated need for treatment with botulinum toxin of any serotype for any indication during the study (other than study intervention)~* Anticipated need for surgery or overnight hospitalization during the study~* Females who are pregnant or breastfeeding and are considering becoming pregnant or donating eggs during the study~* Known immunization or hypersensitivity to any botulinum toxin serotype~* History of clinically significant (per investigator's judgment) drug or alcohol abuse within the last 6 months~* Lower facial and neck hair, scarring (e.g., acne), or other abnormal variations that may interfere with photography (such that photograph is not acceptable)~* Tattoos, jewelry, or clothing that cannot be removed, and that obscure the target area of interest

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BOTOX (Type: EXPERIMENTAL): BOTOX (OnabotulinumtoxinA) was injected into the platysma muscle on Day 1
- Placebo (Type: PLACEBO_COMPARATOR): Placebo will be injected into the platysma muscle on Day 1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects diagnosed with type 2 diabetes mellitus and treated with either diet or single oral drug therapy~* Diet treated subjects: 7.5% \< HbA1c \< 10%~* Single oral drug therapy subjects: 7.0% \< HbA1c \< 9.5%~* Body Mass Index (BMI): max 40 kg/m\^2~Exclusion Criteria:~* Subjects treated with thiazolidinediones or insulin~* Subjects with any serious medical conditions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older, of either gender, and of any race~* Has never been treated with cisplatin and is to receive the first course of cisplatin-based chemotherapy (≥60 mg/m2)~* Karnofsky performance score of ≥60~* Predicted life expectancy of ≥4 months~* Adequate bone marrow, kidney, and liver function~Exclusion Criteria:~* Contraindication to cisplatin, granisetron, or dexamethasone~* Is pregnant or breast feeding~* Has previously received cisplatin or subject is planning to receive multiple days of cisplatin in a single cycle~* Has taken the following agents within the last 48 hours 5-HT3 antagonists,Phenothiazines,Benzamides,Domperidone,Cannabinoids,NK1 antagonist, Benzodiazepines~* Scheduled to receive any other chemotherapeutic agent with an emetogenicity level of 4 or above (Hesketh Scale) from Day 2 through Day 6, except on Day 1.~* Scheduled to receive any radiation therapy to the abdomen or pelvis from Day -5 through Day 6~* Has received systemic corticosteroids or sedative antihistamines within 72 hours of Day 1 of the study except as premedication for chemotherapy (e.g., taxanes, pemetrexed)~* Symptomatic primary or metastatic CNS disease.~* Has ongoing vomiting, retching, clinically significant nausea caused by any etiology, or has a history of anticipatory nausea and vomiting.~* Has vomited and/or has had dry heaves/retching within 24 hours prior to the start of cisplatin-based chemotherapy on Day 1 in Cycle 1.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo + Granisetron + Dexamethasone (Type: PLACEBO_COMPARATOR): Day 1: Placebo + Granisetron (10 mcg/kg IV)+ dexamethasone (20 mg PO) Days 2-4: Dexamethasone (8 mg PO) will be administered orally BID.
- Rolapitant (Type: EXPERIMENTAL): Day 1: Rolapitant (200 mg PO) + Granisetron (10 mcg/kg IV)+ dexamethasone (20 mg PO) Days 2-4: Dexamethasone (8 mg PO) will be administered orally BID.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Participants diagnosed with symptomatic or nonsecretory multiple myeloma~* Participants who have not received chemotherapy and are not hematopoietic stem cell transplantation candidates~* Participants with a measurable lesion~* Life expectancy greater than or equal to 3 months~Exclusion Criteria:~* Previously received treatment for Multiple Myeloma~* Greater than or equal to Grade 2 peripheral neuropathy or neuropathic pain~* Myocardial infarction within 6 months prior to enrollment or uncontrolled angina, severe uncontrolled ventricular arrhythmias, or clinically significant conduction system abnormalities~* Patient is known to be seropositive for the human immunodeficiency virus (HIV), Hepatitis B surface antigen-positive or active hepatitis C infection~* Active prior malignancy diagnosed within the last 5 years~* Female participant who is pregnant or breast-feeding~* Participant is enrolled in another clinical research study and/or is receiving an investigational agent

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase I: JNJ-26866138 0.7 mg/m2 (Type: EXPERIMENTAL): JNJ-26866138 0.7 mg/m2 on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 4 cycles.
- Phase I: JNJ-26866138 1.0 mg/m2 (Type: EXPERIMENTAL): JNJ-26866138 1.0 mg/m2 on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 4 cycles
- Phase I: JNJ-26866138 1.3 mg/m2 (Type: EXPERIMENTAL): JNJ-26866138 1.3 mg/m2 on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 4 cycles
- Phase II: JNJ-26866138 1.3 mg/m2 (Type: EXPERIMENTAL): JNJ-26866138 1.3 mg/m2 on Days 1, 8, 22 and 29 of 6-week cycle for 5-9 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 9 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MiDAS I (Mild® Decompression Alternative to Open Surgery): Vertos Mild Patient Evaluation Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Symptomatic Lumbar Spinal Stenosis (LSS) primarily caused by dorsal element hypertrophy.~* Prior failure of conservative therapy.~* Radiologic evidence of LSS (L3-L5), Ligamentum flavum \> 2.5mm, confirmed by pre-op MRI and/or CT.~* Central canal cross sectional area ≤ 100 square mm.~* Anterior listhesis ≤ 5.0mm.~* Able to walk at least 10 feet unaided before being limited by pain.~* Available to complete 12 weeks of follow-up.~* Consistent with the intended labeling statement for use.~* Able to use all package components to perform the procedure.~* A signed Informed Consent Form is obtained from the patient.~Exclusion Criteria:~* Prior surgery at intended treatment level.~* History of recent spinal fractures with concurrent pain symptoms.~* Disabling back or leg pain from causes other than LSS (e.g. acute compression fracture, metabolic neuropathy, or vascular claudication symptoms, etc.).~* Significant / symptomatic disk protrusion or osteophyte formation.~* Excessive / symptomatic facet hypertrophy.~* Bleeding disorders and/or current use of anti-coagulants.~* Use of acetylsalicylic acid (ASA) and/or non-steroidal anti-inflammatory drug (NSAID) within 5 days of treatment.~* Epidural steroids within prior three weeks.~* Inability of the patient to lie prone for any reason with anesthesia support (e.g. chronic obstructive pulmonary disease (COPD), obesity, etc.).~* Any potential wound healing pathologies that may compromise outcomes, including diabetes, excessive smoking history, cancer, connective tissue diseases, recent spine radiation and severe COPD.~* Dementia and/or inability to give informed consent.~* Pregnancy.~* Intended treatment that is defined by the product labeling contraindications.~* On Workman's Compensation or considering litigation associated with back pain.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- interlaminar decompression (Type: OTHER): Commercially available product (mild® Device Kit) used to perform interlaminar decompression

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult male and female~* Documented diagnosis of pyuria~* Documented diagnosis of cUTI or Acute Pyelonephritis (AP)~Exclusion Criteria:~* Receipt of effective antibacterial drug therapy for cUTI for more than 24 hours during the previous 72 hours prior to randomization~* A urine culture result is resistant to meropenem or a gram negative pathogen is not identified or more than 2 microorganisms are isolated or a confirmed fungal UTI is identified~* Required use of nonstudy systemic bacterial therapy~* Suspected or confirmed prostatitis or urinary tract symptoms attributable to sexually transmitted disease~* Patients with perinephric or renal abscess~* Patients with renal transplantation or receiving hemodialysis or peritoneal dialysis~* Abnormal labs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cefepime/VNRX-5133 (taniborbactam) (Type: EXPERIMENTAL): Cefepime/VNRX-5133 administered q8h intravenously (IV) over a 2-hour period.
- Meropenem (Type: ACTIVE_COMPARATOR): Meropenem will be administered q8h IV over 30 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Schirmers of \< 5 mm at 5 minutes~* TFBUT: less than 10 seconds~* Corneal staining of \>3 of 15: conjunctival staining of \>3 of 18~* Ocular Surface Disease Index of \> 50~* Presumed best corrected vision of 20/60 or better~Exclusion Criteria:~* Acute or inflammatory corneal disease~* Pregnancy or lactation~* Monocular status~* Punctal occlusion within 30 days~* Ocular surgery within 3 months~* Corneal thinning of \>50%~* Active corneal infection~* History of ocular malignancy~* Retinal neovascularization~* Current use of topical cyclosporin A

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Thymosin Beta 4 eye drops (Type: EXPERIMENTAL): It is a preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, six times daily for 28 days
- Vehicle Control (Type: PLACEBO_COMPARATOR): It is composed of the same excipients as RGN-259 but does not contain Tβ4 for direct instillation into each eye, six times daily for 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Documented HAE~* Normal C1q level~* Relatively frequent angioedema attacks (at least 2 per month on average)~Exclusion Criteria:~* Low C1q level~* B-cell malignancy~* Presence of anti-C1INH autoantibody~* History of allergic reaction to C1INH or other blood products~* Narcotic addiction~* Current participation in any other investigational drug study or within the past 30 days~* Participation in a C1 esterase inhibitor trial, or received blood or a blood product in the past 90 days~* Pregnancy or lactation~* Any clinically significant medical condition, such as renal failure, that in the opinion of the investigator would interfere with the subject's ability to participate in the study

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- C1INH-nf First, then Placebo (Type: EXPERIMENTAL): 1,000 Units (U) of C1INH-nf administered intravenously (IV) every 3 to 4 days (approximately twice weekly) for 12 weeks, followed by matching placebo (saline) administered IV every 3 to 4 days for 12 weeks.
- Placebo First, then C1INH-nf (Type: EXPERIMENTAL): Matching placebo (saline) administered IV every 3 to 4 days (approximately twice weekly) for 12 weeks, followed by 1,000 U of C1INH-nf administered IV every 3 to 4 days for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: AD109 Dose Finding in Mild to Moderate OSA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* AHI between 5 and 20 events/h~* PGI-S equal to or higher than 1, or one or more of the following symptoms:~  * Snoring or nightime gasping/choking~ * Daytime sleepiness, fatigue or decreased concentration~ * Nonrefreshing sleep, sleep fragmentation (including from nocturia), or morning headache~ * Irritability, decreased mood or libido~Exclusion Criteria:~* History of narcolepsy.~* Clinically significant craniofacial malformation.~* Clinically significant cardiac disease (e.g. rhythm disturbances, coronary artery disease or heart failure or hypertension requiring more than 2 medications for control).~* CPAP should not be used for at least 2 weeks prior to the study~* History of using oral or nasal devices for the treatment of OSA may enroll as long as the devices are not used during participation in the study.

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Sequence ABC (Type: OTHER): AD109 Dose 1- 75 mg (A), then AD109 Dose 2- 37.5 mg (B), then Placebo (C).
- Sequence ACB (Type: OTHER): AD109 Dose 1- 75 mg (A), then Placebo (C) then AD109 Dose 2- 37.5 mg (B)
- Sequence BAC (Type: OTHER): AD109 Dose 2- 37.5 mg (B), then AD109 Dose 1- 75 mg (A), then Placebo (C)
- Sequence BCA (Type: OTHER): AD109 Dose 2- 37.5 mg (B), then Placebo (C), then AD109 Dose 1- 75 mg (A)
- Sequence CAB (Type: OTHER): Placebo (C), then AD109 Dose 1- 75 mg (A), then AD109 Dose 2- 37.5 mg (B)
- Sequence CBA (Type: OTHER): Placebo (C), then AD109 Dose 2- 37.5 mg (B), then AD109 Dose 1- 75 mg (A)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Paradigm Shift in the Treatment of Patients With ACS

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Men or non-pregnant women \>18 years of age and \< 75 years of age~* Patients undergo cardiac catheterization for ACS. Patients with STEMI, NSTEMI, and UAP will be included. STEMI will be defined as continuous chest pain for \>30 minutes, arrival at the hospital within 12 hours from chest pain onset, ST-segment elevation \>0.1 mV in at least two contiguous leads, or new left bundle-branch block on the 12-lead electrocardiogram (ECG), and elevated cardiac markers (troponin T/I or creatine kinase-MB). NSTEMI will be defined as a progressive crescendo pattern of angina or angina at rest, in the absence of ST-segment elevation on the 12-lead ECG, with elevated cardiac markers. UAP will be defined as new onset angina, progressive crescendo pattern of angina, or angina at rest.~* Culprit lesion located in a native coronary artery~* TIMI flow grade 3 and diameter stenosis \< 70% on angiogram~* Definite erosion defined by OCT~* Patients able to provide written informed consent~Exclusion Criteria:~Left ventricular ejection fraction \< 30%.~* Life expectancy \< 1 year.~* Contraindication to the contrast media.~* Creatinine level \> 2.0 mg/dL or end-stage kidney disease.~* Serious liver dysfunction.~* Patients with hemodynamic or electrical instability (including shock).~* Any contraindication against the use of ticagrelor.~* Investigator considers the patient is not suitable.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Patients with ACS treated medically (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Investigate the Safety and Tolerability of NPSP558, for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study in Hungary

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Patients who meet all the following inclusion criteria can be enrolled into this study:~1. Signed and dated informed consent form (ICF) before any study-related procedures are performed~2. Previously completed 24 weeks of therapy and 4 weeks of follow-up in the REPLACE study, OR Enrolled in REPLACE and dropped out during optimization, but currently meet inclusion/exclusion criteria for REPLACE~3. Able to perform daily SC self-injections of study medication (or have a designee perform injection) via a multidose injection pen into the thigh~4. Willingness and ability to understand and comply with the protocol~5. Women who are: (1) postmenopausal defined as 12 months amenorrhea with appropriate serum follicle stimulating hormone (FSH) levels (\> 40 IU/L); (2) surgically sterilized; OR (3) of childbearing potential with a negative pregnancy test at screening and who consent to use two acceptable methods of contraception for the duration of the study, with pregnancy testing at every scheduled visit during the treatment period . Female partners (who are of childbearing potential) of male study patients must also use acceptable forms of contraception during their partner's participation~Exclusion Criteria:~Patients who meet any of the following exclusion criteria at baseline (Visit 1) are not eligible for enrollment in this study:~1. Any condition that, in the investigator's opinion after consultation with the sponsor, would preclude the safe use of NPSP558~2. Any disease or condition in the opinion of the investigator that has a high probability of precluding the patient from completing the study or where the patient cannot or will not appropriately comply with study requirements~3. Pregnant or lactating woman

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- NPSP558 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete